Search

Illumina Inc

Gesloten

SectorGezondheidszorg

269.35 -0.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

268.35

Max

271.41

Belangrijke statistieken

By Trading Economics

Inkomsten

-268M

-134M

Verkoop

68M

1.2B

K/W

Sectorgemiddelde

49.004

49.241

EPS

1.31

Winstmarge

-11.562

Werknemers

8,600

EBITDA

80M

330M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-7.53% downside

Dividenden

By Acuity

Volgende Winsten

29 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

11B

40B

Vorige openingsprijs

269.76

Vorige sluitingsprijs

269.35

Illumina Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2026, 23:26 UTC

Illumina Inc shares advanced modestly higher in after-market hours on Friday, recovering from a slight decline following the regular session's close.

22 okt 2026, 23:06 UTC

Illumina Inc shares are modestly higher in after-market trading, remaining stable around the midpoint of their one-month trading range.

21 okt 2026, 23:06 UTC

Illumina Inc's shares advanced in after-market trading on Wednesday, remaining above its 20-day moving average and near the upper end of its one-month range.

20 okt 2026, 20:08 UTC

Illumina Inc shares are trading higher compared to Monday's close, having reached a peak earlier in the session before pulling back slightly.

19 okt 2026, 20:01 UTC

News

Canaccord analyst Kyle Mikson raised Illumina's price target to $300.00 from $205.00 while maintaining a Hold rating.

17 okt 2026, 00:01 UTC

Illumina Inc's shares are declining in after-market trading, reversing an earlier gain and remaining significantly below their 20-day moving average.

16 okt 2026, 23:41 UTC

Illumina Inc shares declined during after-market hours, continuing a downward trend over three sessions and remaining significantly below the 20-day moving average.

15 okt 2026, 23:06 UTC

Illumina Inc's shares rose in after-market trading, recovering from an initial dip to peak before settling slightly lower.

14 okt 2026, 20:07 UTC

News

Illumina Inc launched the BioInsight Platform, enhancing genomic research with integrated AI tools and updated DRAGEN v4.6 software for cloud and CPU environments.

13 okt 2026, 20:01 UTC

News

TD Cowen analyst Dan Brennan raised Illumina's price target to $270 from $210 while maintaining a Hold rating, despite the stock declining in today's session.

12 okt 2026, 23:21 UTC

Illumina Inc shares declined in after-market hours, shifting from a slight gain to a loss, amid notable declines in trading.

9 okt 2026, 20:01 UTC

Illumina Inc shares are sharply higher, diverging from their recent trend of higher daily closes since Thursday's close amid a broader market backdrop.

8 okt 2026, 23:05 UTC

Illumina Inc shares are lower in after-market hours, following a slight dip earlier in the session.

7 okt 2026, 19:53 UTC

News

Illumina Inc shares fell sharply today as Barclays maintained its Underweight rating but raised its price target to $200 from $160.

6 okt 2026, 23:20 UTC

Illumina Inc is trading modestly higher in after-market hours, reaching a peak near the upper end of its one-month range and above its 20-day moving average.

5 okt 2026, 20:01 UTC

News

Illumina Inc shares rise sharply as RBC Capital raises the price target to $310 from $230 while maintaining an Outperform rating.

2 okt 2026, 23:26 UTC

Illumina Inc is seeing a slight decline in after-market trading, following a strong one-month performance near the upper end of its recent range.

1 okt 2026, 23:41 UTC

Illumina Inc's shares advanced modestly higher in after-market trading, maintaining a position well above its 20-day moving average despite retracing from an earlier high.

30 sep 2026, 23:40 UTC

Illumina Inc is advancing in after-market trading, moving higher alongside the broader market, following notable volatility and positive U.S. GDP growth data revisions.

29 sep 2026, 23:01 UTC

Illumina Inc is seeing a modest rise in after-market trading, reaching its highest level since Tuesday and remaining above its 20-day moving average.

28 sep 2026, 19:16 UTC

News

Piper Sandler raised Illumina's price target to $305.00 from $225.00, maintaining an Overweight rating as shares trade roughly flat since Friday.

25 sep 2026, 23:05 UTC

Illumina Inc's shares traded modestly lower in after-market hours, following a decline from earlier highs, despite strong gains over the past month.

24 sep 2026, 23:06 UTC

Social Media

Illumina Inc is declining in after-market hours after retracing from an earlier peak, despite a recent strong performance above its 20-day moving average.

23 sep 2026, 23:01 UTC

Social Media

Illumina Inc is seeing notable after-market gains following commentary on a new gene-editing mechanism, reflecting volatility after an initial dip earlier in the session.

22 sep 2026, 20:06 UTC

Illumina Inc is advancing, continuing its upward trajectory since Monday, peaking in the late afternoon and remaining above the 20-day moving average.

21 sep 2026, 20:06 UTC

Illumina Inc shares fell modestly after a mid-morning peak, though they remain above the 20-day moving average and near the upper end of their one-month range.

18 sep 2026, 23:06 UTC

Illumina Inc's stock is advancing in after-market trading, supported by mixed economic data and remaining above its 20-day moving average.

17 sep 2026, 23:06 UTC

Illumina Inc is trading modestly higher in after-market hours, supported by strong broader market performance and recent gains over the past month.

16 sep 2026, 23:01 UTC

Illumina Inc. is up in after-market trading, following five consecutive sessions of gains and trading significantly above its 20-day moving average.

15 sep 2026, 23:01 UTC

Illumina Inc's shares are trading higher in after-market hours, benefiting from a broader market rally despite mixed macroeconomic signals.

Peer Vergelijking

Prijswijziging

Illumina Inc Prognose

Koersdoel

By TipRanks

-7.53% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 249.125 USD  -7.53%

Hoogste 320 USD

Laagste 113 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Illumina Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

16 ratings

9

Buy

4

Hold

3

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat